Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma

Omar Castaneda-Puglianini, Julio C Chavez


Immunotherapy has revolutionized the treatment of cancers. There are several approaches, including naked monoclonal antibodies, antibody–drug conjugates, immune-checkpoint inhibitors and chimeric antigen receptor T cell therapies with important success. Bispecific antibodies represent a novel immunotherapeutic approach for the treatment of several malignancies, in particular non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). Early-phase studies have shown encouraging clinical activity in poor-risk B cell NHL and MM. Several constructs are currently available and in clinical development for the treatment of these malignancies. Here, we present a narrative review of the most current data on bispecific antibodies in B cell NHL and MM.

Article Details

Article Type




Publication Dates

Accepted: ; Published: .


Castaneda-Puglianini O, Chavez JC. Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma. Drugs Context. 2021;10:2021-2-4.

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.